Abstract: An aqueous lubricant emulsion for medical or food apparatus, comprising: (a) 5 wt % to 30 wt % of a mineral oil; (b) 5 wt % to 30 wt % of an emulsifier system consisting of two emulsifiers selected from the group consisting of sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, oleyl alcohol ether, triethanolamine oleate, wherein the mass ratio of the two emulsifiers is in a range of 2:8 to 8:2; (c) 0.5 wt % to 5 wt % of one or more coemulsifiers selected from the group consisting of fatty alcohols, long-chain fatty acids, and diisooctyl succinate sulfonates; and (d) the balance of water. A method for washing medical or food apparatus including the step of subjecting the medical or food apparatus to a treatment using the lubricant emulsion according to the invention after a washing step for the medical or food apparatus is also described.

Abstract: Disclosed are methods in which an aliphatic polyether selected from polyalkylene oxides with monomer units having 3 to about 10 carbon atoms and polyvinyl ethers with ether groups having 2 to about 8 carbon atoms is added to a hydrocarbon lubricant; such methods in which the hydrocarbon lubricant comprises oxidation products that are dissolved by the addition of the polyether or polyvinyl ether; hydrocarbon lubricants containing a polyether selected from polyalkylene oxides with monomer units having 3 to about 10 carbon atoms and polyvinyl ethers with ether groups having 2 to about 8 carbon atoms; methods of lubricating machines with these lubricants; lubrication systems including these hydrocarbon lubricants; and machines including these lubrication systems.

Abstract: Composition A low irritancy cleansing composition comprises: (a) an anionic surfactant compound of formula (I): wherein R1 represents a C4-36 substituted or unsubstituted hydrocarbyl group; each of R2, R3, R4 and R5 independently represents a hydrogen atom or a C1-4 alkyl group and wherein at least one of R2, R3, R4 and R5 is not hydrogen and M+ represents a cation; (b) an amphoteric surfactant; and (c) an alkoxylated non-ionic species; wherein the molar ratio of component (a) to component (b) is from 0.5:1 to 2:1 and wherein the ratio of the mass of component (c) to the combined mass of components (a) and (b) is less than 1.2:1.

Abstract: Composition containing an aqueous phase, at least 35% by weight of jojoba oil relative to the total weight of the composition, and at least one sucrose fatty acid ester. The composition is preferably in the form of a gel. It may be used, in particular, for removing makeup from the skin and/or the eye area and/or the lips.

Abstract: A bar soap comprising a pyrithione source, a soap surfactant, and a pH adjusting agent selected from a group consisting of ammonia solution, triethanolamine, diethanolamine, monoethanolamine, potassium hydroxide, sodium hydroxide, soluble carbonate salts, and combinations thereof, wherein the bar soap attains a pH of greater than or equal to 10.7. A process of inhibiting the formation of a discoloration in a bar soap comprising pyrithione sources by adding pH adjusting agent to attain a pH of greater than or equal to 10.7. A process of inhibiting the formation of a discoloration in a bar soap caused by dissolved ferric ions and/or cupric ions and pyrithione sources in the bar, comprising the step of adding from about 0.3% to about 20% soluble carbonate salt during manufacturing of the bar soap.

Abstract: An cleaning composition and process for cleaning post-chemical mechanical polishing (CMP) residue and contaminants from a microelectronic device having said residue and contaminants thereon. The cleaning compositions include novel corrosion inhibitors. The composition achieves highly efficacious cleaning of the post-CMP residue and contaminant material from the surface of the microelectronic device without compromising the low-k dielectric material or the copper interconnect material.

Abstract: It is disclosed a cleaning liquid for stripping and dissolving a photoresist pattern having a film thickness of 10-150 ?m, which contains (a) 0.5-15 mass % of a quaternary ammonium hydroxide, such as tetrapropylammonium hydroxide and tetrabutylammonium hydroxide, (b) 65-97 mass % of a water-soluble organic solvent, such as dimethylsulfoxide or a mixed solvent thereof with N-methyl-2-pyrrolidone, sulforane, etc., and (c) 0.5-30 mass % of water, and a method for treating a substrate therewith.

Abstract: A rinse aid composition comprising: a) a polymer comprising an acrylic acid backbone and alkoxylated side chains, said polymer comprising a molecular weight of from about 4,000 to about 22,000, the polymer comprising from about 20 wt % to about 50 wt % of an alkylene oxide; and b) a low foaming nonionic surfactant.

Abstract: A detergent composition for metal according to the present invention contains a specific non-ionic surfactant, a specific nitrogen-containing organic compound, a specific carboxylic acid or salt thereof, and a specific alkanol amine, and has a pH of at least 9 that is measured at 25° C. when the detergent composition is diluted to 1% by mass of an aqueous solution. According to the present invention, the detergent composition for metal having excellent corrosion inhibition properties, excellent effluent treatment properties, excellent foaming suppressing properties and excellent liquid stability in addition to high detergent properties for metal, can be provided.

Abstract: The invention provides improvements in the primary detergency of detergents for washing textiles, particularly against oily stains and/or stains containing fat. These improvements are realized through the use of certain polycarbonate-, polyurethane-, and/or polyurea-polyorganosiloxane compounds or precursor compounds usable in the production thereof having certain reactive groups.

Abstract: The present invention provides: (1) crystals of a dipeptide which do not substantially comprise a dipeptide comprising D-amino acid as a constituent or a polypeptide consisting of three or more amino acids; and (2) crystals of a dipeptide which do not substantially comprise a dipeptide comprising D-amino acid as a constituent, a polypeptide consisting of three or more amino acids, or an amino acid amide; and a process for producing the dipeptide crystals.

Abstract: Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament.

Abstract: The embodiments provide prodrug compounds of Formulae I-XV. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XV that provides controlled release of an opioid. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an opioid from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.

Abstract: A method of losing weight which is effective for, but not limited to, the treatment of obesity in an individual includes administering nutrients high in protein by a combination of enteral feeding and oral feeding over a predetermined time period. The predetermined time period is preferably defined by three consecutive time segments, wherein the conducting of the enteral feeding occurs during the first time segment, preferably by nasogastric intubation and the infusion of a high protein solution. Subsequently and consecutively the oral feeding proceeds over a second time segment and a third time segment, where the nutrients in the second time segment are a combination of a drinkable solution and solid food and the nutrients administered during the third time segment comprise a balanced, low-calorie diet.

Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Abstract: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.

Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.

Abstract: A method for inhibiting survival of cancer cells in a subject is disclosed. The method comprises administering to a subject in need thereof a therapeutically effective amount of fibrillar albumin. The preparation of the fibrillar albumin comprises: (i) forming a solution comprising an isolated and/or purified globular albumin; (ii) adding a detergent to the solution containing the isolated and/or purified globular albumin, wherein the detergent is one selected from the group consisting of sodium dodecyl sulfate (SDS) and n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate; (iii) applying the solution to a molecular sizing column with a pore size that permits separation of a protein with a molecular weight of at least about 70 kDa so as to promote column-induced formation of the fibrillar albumin from the isolated and/or purified globular albumin; and (iv) eluting the fibrillar albumin from the column, wherein the eluted albumin has a fibrillar structure.

Abstract: An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that stimulates an androgen binding site, and a method of screening for a drug for the prophylaxis or treatment of abdominal pressure incontinence, which includes electrostimulating the abdominal muscles or a nerve controlling them of an animal to increase the abdominal pressure, and measuring the leak point pressure at that time.

Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.

Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.

Abstract: A cosmetic or pharmaceutical composition that includes a peptide hydrolyzate which is enriched in soothing bioactive peptide in a physiologically acceptable medium is described. Methods for applying such compositions to the skin are also described, in particular where the active principle activates 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase in skin cells to treat skin irritations.

Abstract: The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.

Abstract: This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biological sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biological sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biological sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.

Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.

Abstract: Provided are proteins and polynucleotides, complexes and compositions containing the proteins, and methods for their use in administration to subjects and for disease treatment. Among the provided proteins and complexes are complexes containing a TGF-beta associated with immunoglobulins (such as IgGs) or functional portions thereof including Fc portions, such as by non-covalent bonds. The provided complexes include those in which the immunoglobulin portion binds to inhibitory Fc? receptors to a greater degree than to activating Fc? receptors. The provided complexes further include those in which the immunoglobulin portion bind to activating Fc? receptors to a greater degree than to inhibitory Fc? receptors. The complexes and compositions can be used for administration to subjects, such as for increasing immunity or decreasing inflammation, such as for treating diseases including autoimmune diseases and cancer.

Abstract: The invention relates to peptides and, in particular, heptapeptides derived from milk casein ?s1 and having anxiolytic activity. The invention also relates to pharmaceutical and food compositions containing said peptides and to the preparation methods thereof.

Abstract: The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.

Abstract: The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximize the beneficial health effects of hesperetin.

Abstract: The invention relates to prodrugs of hydroxyl-substituted adamantane compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.

Abstract: The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.

Abstract: The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family. Also provided are means and methods for overcoming host immunological tolerance to death receptors. The vaccines are useful against cancer cells and other death receptor bearing target cells within the host, and can be used in both therapeutic and prophylactic settings. The vaccines are also useful for diagnostic testing of the immunocompetence of a host.

Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.

Abstract: Disclosed herein are compositions comprising a drug combination that comprises ZD and S3I-201, Das and S3I-201, ZD and AG490, or Das and AG490. The disclosed drug combinations target two or more functional elements such as EGFR or Src and Stat3 or Jaks in pancreatic cancer cells. Also disclosed herein are methods of using the disclosed compositions to cytotoxically affect pancreatic cancer cells and methods of making the disclosed compositions.

Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.

Abstract: Compositions (including pharmaceutical compositions, foods, supplements, toys and treats) comprising a microbial exopolysaccharide are provided as well as methods for preventing or reducing diarrhea in a mammal wherein the method comprises administering a therapeutically amount of a microbial exopolysaccharide to a mammal in need thereof.

Abstract: The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat.

Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.

Abstract: The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured.

Abstract: Diuretic bioactivity profiles of phase inversion micronized furosemide and furosemide co-precipitated with Eudragit L100, and mixtures of those formulations with stock furosemide, reduced or eliminated the rapid spike in diuresis associated with immediate release formulations and maintained cumulative urine output. Of the formulations tested, each of a mixture of micronized furosemide with stock furosemide, and Eudragit L100 polymer with stock furosemide demonstrated optimal diuretic bioactivity profiles in subjects.

Abstract: A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.

Abstract: The present invention relates to the use of 25-hydroxy-vitamin D3 to improve the general health status of female animals at least during gestation and/or lactation. The invention also relates to the use of 25-hydroxy-vitamin D3 in animal breeding. More particular, the invention relates to the use of 25-hydroxy-vitamin D3 for improving litter size and vitality of piglets in pig breeding and for providing better body frame and increasing gestation backfat gain, reducing lactation backfat loss and increasing lactation feed intake of sows and gilts.

Abstract: Following a diagnosis of ectopic pregnancy, at least one aromatase inhibitor, is administered to a patient, either alone or in combination with other aromatase inhibitors or therapeutic agents or as an adjuvant to conservative surgical treatment, such as laparoscopy, to prevent the establishment and/or continuation of the ectopic pregnancy. In certain preferred embodiments, the aromatase inhibitor is administered in conjunction with methotrexate.

Abstract: The present invention provides compositions and methods for cytoprotection. In particular, it provides zinc chelate compositions comprising at least one zinc ion and at least one aminothiol ligand.

Abstract: The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.

Abstract: The present invention relates to linear and cyclic guanidine derivatives, method of preparation and uses thereof, pharmaceutical compositions to be used as antifungal agents, in particular against Candida species.